248 related articles for article (PubMed ID: 27009179)
21. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices.
MMWR Recomm Rep; 1996 Apr; 45(RR-4):1-18. PubMed ID: 8602127
[TBL] [Abstract][Full Text] [Related]
22. The potential health and economic impacts of new tuberculosis vaccines under varying delivery strategies in Delhi and Gujarat, India: a modelling study.
Clark RA; Portnoy A; Weerasuriya CK; Sumner T; Bakker R; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
medRxiv; 2023 Sep; ():. PubMed ID: 37808744
[TBL] [Abstract][Full Text] [Related]
23. Heterogeneity in tuberculosis transmission and the role of geographic hotspots in propagating epidemics.
Dowdy DW; Golub JE; Chaisson RE; Saraceni V
Proc Natl Acad Sci U S A; 2012 Jun; 109(24):9557-62. PubMed ID: 22645356
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of routine adolescent vaccination with an M72/AS01
Harris RC; Quaife M; Weerasuriya C; Gomez GB; Sumner T; Bozzani F; White RG
Nat Commun; 2022 Feb; 13(1):602. PubMed ID: 35105879
[TBL] [Abstract][Full Text] [Related]
25. AdHu5Ag85A Respiratory Mucosal Boost Immunization Enhances Protection against Pulmonary Tuberculosis in BCG-Primed Non-Human Primates.
Jeyanathan M; Shao Z; Yu X; Harkness R; Jiang R; Li J; Xing Z; Zhu T
PLoS One; 2015; 10(8):e0135009. PubMed ID: 26252520
[TBL] [Abstract][Full Text] [Related]
26. Is neglect of self-clearance biasing TB vaccine impact estimates?
Scarponi D; Clark RA; Weerasuriya CK; Emery J; Houben RMGJ; White R; McCreesh N
BMJ Glob Health; 2023 Aug; 8(8):. PubMed ID: 37558271
[TBL] [Abstract][Full Text] [Related]
27. Knowledge of tuberculosis and vaccine trial preparedness in Lima, Peru.
Shu E; Sobieszczyk ME; Sal Y Rosas VG; Segura P; Galea JT; Lecca L; Sanchez J; Lama JR
Int J Tuberc Lung Dis; 2017 Dec; 21(12):1288-1293. PubMed ID: 29297450
[TBL] [Abstract][Full Text] [Related]
28. Mathematical model to assess vaccination and effective contact rate impact in the spread of tuberculosis.
Nkamba LN; Manga TT; Agouanet F; Mann Manyombe ML
J Biol Dyn; 2019 Dec; 13(1):26-42. PubMed ID: 31793413
[TBL] [Abstract][Full Text] [Related]
29. Childhood tuberculosis: epidemiology, diagnosis, treatment, and vaccination.
Tsai KS; Chang HL; Chien ST; Chen KL; Chen KH; Mai MH; Chen KT
Pediatr Neonatol; 2013 Oct; 54(5):295-302. PubMed ID: 23597517
[TBL] [Abstract][Full Text] [Related]
30. The role of geospatial hotspots in the spatial spread of tuberculosis in rural Ethiopia: a mathematical model.
Shaweno D; Trauer JM; Denholm JT; McBryde ES
R Soc Open Sci; 2018 Sep; 5(9):180887. PubMed ID: 30839742
[TBL] [Abstract][Full Text] [Related]
31. Engaging adolescents in tuberculosis and clinical trial research through drama.
Schmidt BM; Abrams A; Tameris M
Trials; 2016 Apr; 17():177. PubMed ID: 27048474
[TBL] [Abstract][Full Text] [Related]
32. Immunization strategies against pulmonary tuberculosis: considerations of T cell geography.
Horvath CN; Xing Z
Adv Exp Med Biol; 2013; 783():267-78. PubMed ID: 23468114
[TBL] [Abstract][Full Text] [Related]
33. Prospects for elimination of childhood tuberculosis: the role of new vaccines.
Hatherill M
Arch Dis Child; 2011 Sep; 96(9):851-6. PubMed ID: 21450742
[TBL] [Abstract][Full Text] [Related]
34. The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model.
Dowdy DW; Chaisson RE; Moulton LH; Dorman SE
AIDS; 2006 Mar; 20(5):751-62. PubMed ID: 16514306
[TBL] [Abstract][Full Text] [Related]
35. Do selective immunisation against tuberculosis and hepatitis B reach the targeted populations? A nationwide register-based study evaluating the recommendations in the Norwegian Childhood Immunisation Programme.
Feiring B; Laake I; Molden T; Håberg SE; Nøkleby H; Seterelv SS; Magnus P; Trogstad L
Vaccine; 2016 Apr; 34(17):2015-20. PubMed ID: 26947498
[TBL] [Abstract][Full Text] [Related]
36. Mycobacterium tuberculosis virulence: insights and impact on vaccine development.
Delogu G; Provvedi R; Sali M; Manganelli R
Future Microbiol; 2015; 10(7):1177-94. PubMed ID: 26119086
[TBL] [Abstract][Full Text] [Related]
37. Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG.
Villarreal DO; Walters J; Laddy DJ; Yan J; Weiner DB
Hum Vaccin Immunother; 2014; 10(8):2188-98. PubMed ID: 25424922
[TBL] [Abstract][Full Text] [Related]
38. The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study.
Spertini F; Audran R; Lurati F; Ofori-Anyinam O; Zysset F; Vandepapelière P; Moris P; Demoitié MA; Mettens P; Vinals C; Vastiau I; Jongert E; Cohen J; Ballou WR
Tuberculosis (Edinb); 2013 Mar; 93(2):179-88. PubMed ID: 23219236
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial.
Thacher EG; Cavassini M; Audran R; Thierry AC; Bollaerts A; Cohen J; Demoitié MA; Ejigu D; Mettens P; Moris P; Ofori-Anyinam O; Spertini F
AIDS; 2014 Jul; 28(12):1769-81. PubMed ID: 24911353
[TBL] [Abstract][Full Text] [Related]
40. [Estimation of the future epidemiological situation of tuberculosis in Japan].
Ohmori M; Yoshiyama T; Ishikawa N
Kekkaku; 2008 Apr; 83(4):365-77. PubMed ID: 18516900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
